Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in ...

For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging ...

PM PST Webcast: A replay of the event will be available for 90 days and can be accessed by visiting the “ Investor Calendar ...

When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life. But, ironically, that life-saving rush of blood can also trigger a second ...

When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.

This video shows, in real time within the first 24 hours of the injection, immune cells (shown in red) rushing into an area injured by ischemic stroke. The peptide treatment (blue) successfully ...

The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

Vera Therapeutics stock rose on FDA acceptance of atacicept BLA for priority review in IgAN, a potential multi-billion dollar ...

Within hours of getting inked, pigments begin migrating through your body, building up in immune tissues and triggering ...

FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting ...

A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...